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Background  Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) 
whereby the host immune system attacks against the myelin. MS affects 
predominantly young adults and leads to neurological disability. Although it has 
worldwide penetrance, MS has different incidence rates in different parts of the world. 
The incidence may also vary among different parts of the country, as seen in Finland. 
The final diagnosis of MS may often be delayed due to the heterogeneity and relapsing 
nature of the disease. Occurring symptoms depend on the location of the 
inflammation in the central nervous system. The most common form of the disease is 
relapsing-remitting multiple sclerosis (RRMS), in which patients typically recover from 
all of their symptoms. Infections are often seen before the disease progresses or 
relapses. Therefore, infectious agents, especially viruses, have been under suspicion 
for triggering an autoimmune reaction that leads to demyelination. Human 
herpesviruses are considered to be possible triggers for MS pathogenesis.  
Objective Most patients who have been diagnosed with MS have oligoclonal bands (OCBs) of 
immunoglobulins in their cerebrospinal fluid (CSF). The OCBs are intrathecally 
produced antibodies mainly consisting of IgG, IgA, and IgM class antibodies. Clinically, 
the most important antibody group in OCB analysis is the IgG class, which was the main 
focus in this study. The objective was to study if the OCBs of patients contain 
antibodies against highly neurotropic and common childhood viruses: human 
herpesvirus-6 (HHV-6) and varicella-zoster virus (VZV). Another objective was to study 
if the patients, who have virus-reactive OCBs in their CSF, have some distinguishable 
features. The main aim was to study the possible role of these viruses in the 
pathogenesis of MS, focusing on the presence of antibodies during the early stages of 
the disease.  
Methods OCB-positive CSF-serum sample pairs were systematically collected over the course of 
one year. A retrospective re-detection of OCBs by isoelectric focusing (IEF) was made, 





 HHV-6 IgG antibodies were analyzed from the serum with immunofluorescence assay 
(IFA). The binding capacity of the IgG antibodies was analyzed and the infections 
(primary vs. past infection) were classified with avidity testing.  
During the clinical evaluation, the medical records of the patients were analyzed 
without knowing the results of the IFA or virus-reactive OCBs. This study has been 
ethically approved.  
Results We had 18 immunocompetent adult patients with serologically primary HHV-6A or 
HHV-6B infections. None of them had any typical signs of a virus infection (e.g. fever 
or rash). Of those 18 patients 11 were diagnosed with MS with a primary infection 
during the early stage of the disease. 
Of 79 patients, 26 had HHV-6A-, HHV-6B-, or VZV –reactive OCBs in their CSF. Of those 
26 patients 62% were diagnosed with MS and had these virus-reactive OCBs during the 
early stage of MS. Patients who had any studied virus-reactive OCBs in their CSF 
seemed to differ from those without, including: more OCBs (p=0.001-0.003), lower 
protein concentration (p=0.012), and higher IgG index (p=0.007-0.014) in the CSF. They 
were also younger (p=0.047). 
Conclusion Virus-reactive OCBs are possibly associated with MS disease pathogenesis. HHV-6 and 
VZV may have some association with MS disease. The pathogenesis of multiple 
sclerosis may have distinguishable subgroups, including pathogenesis triggered by 







Multippeliskleroosi eli MS-tauti on keskushermoston autoimmuunitauti, jossa potilaan 
oma immuunijärjestelmä tuhoaa ensisijaisesti keskushermoston hermotukikudosta, 
myeliiniä. MS-tauti on yksi yleisimmistä työkyvyttömyyttä aiheuttavista nuorten 
aikuisten neurologisista taudeista. Tautia tavataan kaikkialla maailmassa, mutta sen 
ilmaantuvuus vaihtelee. Vaihtelua on jopa maan sisällä, kuten nähdään myös 
Suomessa. Diagnoosin varmistuminen voi joskus viivästyä, sillä oireet ja taudinkuva 
voivat olla joillakin potilailla hyvinkin vaihtelevia. Potilaan oireisto määräytyy sen 
mukaan missä kohtaa keskushermostoa tulehdus sijaitsee. Tyypillisin taudin 
ilmentymä on relapsoiva-remittoiva MS-tauti (RRMS), jossa vaihtelevat oirejaksot ja 
oireettomat jaksot. Erilaisia tulehduksia nähdään usein ennen MS-taudin puhkeamista 
ja ennen oirejaksoja. Tämän vuoksi etenkin virusten, ja erityisesti ihmisen 
herpesvirusten, on ajateltu liittyvän MS-taudin puhkeamiseen. 
Tavoitteet Suurimmalla osalla MS-tautia sairastavista potilaista nähdään aivo-selkäydinnesteessä 
keskushermostoperäisiä IgG-luokan vasta-aineita oligoklonaalisina fraktioina (OCB). 
Oligoklonaalisia fraktioita voidaan nähdä myös IgM- sekä IgA-luokan vasta-aineilla. 
Ainakin toistaiseksi IgG-luokan OCB:t ovat ainoita, jotka ovat kliinisessä käytössä ja 
näin ollen ainoastaan näitä tarkastelimme tutkimuksessamme. Tutkimuksemme 
yhtenä tarkoituksena oli selvittää onko osa potilaiden OCB:sta ihmisen herpesvirus-6:n 
(HHV-6) tai vesirokkoviruksen (VZV) vasta-aineita. Toisena tarkoituksena oli selvittää 
onko näillä potilailla, joilla osa OCB:sta on virusperäisiä vasta-aineita, joitakin 
erityispiirteitä. Tutkimuksen varsinaisena tavoitteena oli tutkia virusten osuutta MS-
taudin patogeneesissä ja keskittyä erityisesti tarkastelemaan edellä mainittuja 






Keräsimme yhden vuoden ajanjaksolta seerumi- ja aivoselkäydinnestenäytteet kaikilta 
Meilahden neurologian klinikalla hoidetuilta potilailta, joilla oli 
keskushermostoperäisiä OCB:ta likvorissa. Teimme retrospektiivisesti kaikille 
näytteille toistetun isoelektrisen fokusoinnin määrittääksemme OCB:t. Käytimme 
affiniteetti-immunoblottausta paikantaaksemme oligoklonaalisten fraktioiden 
sisältämät mahdolliset HHV-6A:n, HHV-6B:n sekä VZV:n vasta-aineet. Seerumin HHV-
6 IgG-luokan vasta-aineet määritettiin epäsuoralla immunofluoresenssilla. IgG-luokan 
vasta-aineen sitoutumisvoimakkuutta analysoimme aviditeetti-testauksella. Näin 
saimme luokiteltua infektion joko primaari-infektioksi tai aikaisemmin sairastetuksi 
infektioksi. Potilaiden kliiniset tiedot kerättiin ja analysoitiin sokkoutetusti ilman 
tietoja laboratoriotuloksista. Tutkimuksella on eettisen toimikunnan hyväksyntä. 
Tulokset Löysimme yhteensä 18 immunokompetenttia aikuista, joilla oli seerumin vasta-
aineiden perusteella HHV-6A tai HHV-6B primaari-infektio. Yhdelläkään näistä 
potilaista ei ollut tyypillisiä virusinfektion oireita (esim. kuume tai ihottuma). Näistä 18 
potilaasta 11:llä diagnosoitiin tuore MS-tauti HHV-6 primaari-infektion aikana. Lisäksi 
kaikista 79 tutkitusta OCB positiivisesta potilaasta 26:lla oli keskushermostoperäistä 
HHV-6A:n, HHV-6B:n tai VZV:n vasta-ainetta oligoklonaalisissa fraktioissa. Näistä 26 
potilaasta 62 %:lla oli näitä virusvasta-aineita varhaisen MS-taudin diagnoosin aikana. 
Potilaat, joilla oli jokin näistä tutkituista keskushermostoperäisistä virusvasta-aineista, 
näyttivät eroavan niistä potilaista, joilla ei ollut lainkaan tutkittuja virusvasta-aineita. 
Heillä oli lukumääräisesti enemmän likvorin oligoklonaalisia fraktioita (p=0.001-0.003), 
pienempi likvorin proteiinimäärä (p=0.012) ja korkeampi likvorin IgG indeksin luku 
(p=0.007-0.014). He olivat lisäksi nuorempia (p=0.047). 
Päätelmät Oligoklonaalisten fraktioiden sisältämät virusvasta-aineet ovat mahdollisesti 
yhteydessä MS-taudin patogeneesiin. Ihmisen herpesvirus-6 sekä vesirokkovirus 
saattavat olla osallisina MS-taudin puhkeamisessa. MS-taudissa on mahdollisesti 





Multiple sclerosis (MS) is one of the most disabling neurological diseases in young adults. It usually 
occurs in previously healthy individuals without any prodromal signs. Presenting symptoms may 
vary from mild paresthesia to disabling motoric deficiency and diplopia. Patients may suffer mild 
recurring symptoms years before being referred to a neurologist. In some cases, it may be extremely 
challenging to definitively diagnose MS. A curative medication for MS is yet to be found. Some new 
immunotherapies significantly reduce the relapses and inflammatory activity that is seen in the MRI 
of the brain. The disease progression can also be moderately delayed with several 
immunotherapies. MS pathogenesis is dependent on leucocyte-mediated demyelination. Drugs that 
reduce the number of activated leucocytes are most effective against relapses of MS. The main 
triggers that cause the immune system to incorrectly attack the host’s own myelin are thought to 
be combinations of genetic predisposition and environmental factors, including viruses.  
Viruses and various infections have been associated with MS pathogenesis for nearly a century. Mild 
infections are usually observed before disease progression and relapse. Human herpesviruses have 
been most studied and they are thought to have some association with MS pathogenesis. Currently, 
Epstein-Barr virus (EBV) is the strongest viral candidate in MS pathogenesis and Human herpesvirus-
6 is also of significant interest in research. Although many different viruses have been actively 
researched during the last decades, an “MS-triggering virus” has not been identified.  
An immune system dysfunction that causes the immune system to attack itself and cause 
demyelination is thought to be the main pathological mechanism in MS disease. Clinical symptoms 
and characteristic white matter lesions are the consequences of the demyelination process in the 
central nervous system (CNS). The presence of intrathecal immunoglobulin antibodies, called 
oligoclonal bands (OCBs), is a highly common finding in cerebrospinal fluid (CSF) of the patients. In 
MS pathogenesis, OCBs are thought to be a sign of immune-system dysfunction and an indicator of 
the possible involvement of an infectious agent.  
The objective of this doctoral study was to investigate the role of viruses during the early stages of 
MS disease, especially focusing on highly neurotropic ones: human herpesvirus-6A (HHV-6A), 
human herpesvirus-6B (HHV-6B), and varicella-zoster virus (VZV). HHV-6 and VZV have 
characteristics that make them highly potential triggers for chronic neurological diseases: I) they 




highly neurotropic, especially HHV-6 that is located in the central nervous system in a latent state, 
and III) they both act as opportunistic pathogens that may be activated when the immune system is 
compromised.  
In our study, we found patients who had serologically confirmed primary HHV-6A/B infections in the 
early stages of MS. We also found patients with early MS who had HHV-6 –reactive OCBs in their 
CSF and patients with VZV-reactive OCBs. The prevalence and possible clinical association of these 




1 LITERATURE REVIEW   
1.1 HUMAN HERPESVIRUS-6 (HHV-6)  
1.1.1 Introduction of the virus 
HHV-6 was first discovered in 1986 in peripheral blood leukocytes of patients with AIDS and patients 
with lymphoproliferative disorders (Salahuddin et al., 1986). It was first called human B-
lymphotropic virus, but later recognized to be a member of the human herpesvirus family and re-
named as HHV-6 (Ablashi et al., 2014, Ablashi et al., 1987). HHV-6 is a beta-herpes virus belonging 
to the herpes virus family along with herpes simplex 1 and 2 (HSV-1 and HSV-2, HHV-1 and HHV-2), 
varicella-zoster virus (VZV, HHV-3), Epstein-Barr virus (EBV, HHV-4), cytomegalovirus (CMV, HHV-5), 
HHV-7, and Kaposi’s sarcoma associated herpesvirus (KSHV, HHV-8).  
HHV-6 was long considered to have two variants: HHV-6A and HHV-6B. These were recently (2012) 
re-classified by the International Committee on Taxonomy of Viruses as two separate viruses 
(Ablashi et al., 2014). HHV-6B is known to cause exanthema subitum – a common childhood illness 
(ES, roseola infantum, sixth disease). The clinical course of ES is typically benign or nearly 
symptomless and self-limiting. Typical symptoms of ES often include fever that is followed by a 
characteristic mild rash (see Figure 1). Complications are uncommon and the primary infection is 
rarely fatal (Campadelli-Fiume et al., 1999). In fulminant cases of exanthema subitum, patients may 





Figure 1.  Typical rash in exanthema subitum. (Photograph is published with the permission of Tiina 
Iisalo) 
 
HHV-6A has not been proven to cause any specific disease, but it is associated with CNS infections 
and chronic neurological diseases, including MS (Portolani et al., 2005). The primary infection 
caused by both HHV-6 viruses is often reported to be mainly asymptomatic; in childhood, HHV-6B 
causes clinical symptoms more often than HHV-6A, which usually leads to a symptomless primary 
infection that occurs soon after HHV-6B (Agut, 2011).  
1.1.2 Characteristic features 
Nearly all people worldwide have had an HHV-6 infection in early childhood. According to data 
gathered from different countries, the seroprevalence of HHV-6 antibodies is between 60-95% of 
the whole population (Krueger and Ablashi, 2003). HHV-6 acquisition appears to be 9-21 months 
(Zerr et al., 2005). After the primary infection, HHV-6 remains in the host in a latent form 
permanently. It enters a state of latency in a small fraction of the host’s cells in different organs, 
especially in salivary glands, peripheral blood lymphocytes, and bronchial glands (Mori and 
Yamanishi, 2007, Pellett et al., 2012, Lyall, 1996). One important site for the presence of the latent 
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form of HHV-6 is the human brain (Chan et al., 2001, Gordon et al., 1996). It also seems to be latent 
in the ganglia of the peripheral nervous system (Hufner et al., 2007). 
HHV-6 is a highly neurotropic virus (Tuke et al., 2004). It is capable of infecting different cell types 
in the central nervous system (CNS): oligodendrocytes, astrocytes, and neurons (De Bolle et al., 
2005). The hiding nature of the virus is associated with its capability of inducing neurological 
diseases, and its re-activation might be the cause of the symptoms (Yao et al., 2010a). In addition to 
neurotropism, HHV-6 is a highly lymphotropic virus, and circulating polymorphonuclear leukocytes 
are the main reservoir of HHV-6 in the blood during the infection (Gautheret-Dejean et al., 2009). In 
addition, HHV-6 has tropism for a variety of other human cells and tissues, which is seen in the wide 
variety of organs the virus is capable of infecting (Ablashi et al., 2010).  
In the primary infections caused by HHV-6, pathological mechanisms are thought to be different 
from those acting during the re-activation of the virus (Kawamura et al., 2011). This can be seen 
when comparing the clinical outcomes of the primary infection (exanthema subitum) with the re-
activation in immunosuppressed patients with organ transplants (i.e. pneumonitis, hepatitis, gastro-
intestinal dysfunctions, and neurological dysfunctions) (Neumann et al., 2009).  
Lately, HHV-6 has been found to be able to integrate into the human genome (Tanaka-Taya et al., 
2004). The condition is called chromosomally-integrated HHV-6 (CIHHV-6). In CIHHV-6, patients may 
have HHV-6-DNA present in the serum or the CSF even when an active HHV-6 infection is not 
present. The clinical significance of CIHHV-6 remains unknown. Many patients are healthy and 
symptomless with CIHHV-6, but a variety of neurological symptoms have been associated with the 
condition in some patients (Montoya et al., 2012).  
1.1.3 Clinical significance in adults 
HHV-6 is an opportunistic pathogen, which is often re-activated when a patient is 
immunocompromised (i.e. patients with organ transplant and hematological malignances) and it is 
capable of causing moderate to severe CNS diseases (Zerr et al., 2002). For the 
immunocompromised patients, HHV-6 is capable of causing severe encephalitis. The symptoms in 
HHV-6-caused encephalitis may be indistinguishable from the herpes-simplex virus -encephalitis 
(Noguchi et al., 2010). Even though immunocompromised patients survive the HHV-6 encephalitis, 




HHV-6 encephalitis as a complication increases the mortality rate in hematopoietic cell transplant 
patients, even when it is not the main cause of death (Bhanushali et al., 2013). After a hematopoietic 
cell transplantation, 30-80% of the patients develop (within 6 weeks) HHV-6B viraemia and some 
patients may experience CNS dysfunction (Hill et al., 2014). The presence of HHV-6B in the CSF of 
patients after hematopoietic cell transplantation, even without a clinical CNS dysfunction, 
significantly increases the mortality risk of the patients (Hill et al., 2014).  
It is thought that HHV-6 re-activation is clinically unnoticeable unless the patient has an insufficient 
immune system (Krueger and Ablashi, 2003). In rare cases, however, HHV-6 can infect 
immunocompetent adults and cause severe infection in the CNS and other organs (i.e. acute liver 
dysfunction) (Sloots et al., 1995, Sawada et al., 2007, Fried et al., 2009, De Simone et al., 2013, 
Cacheux et al., 2005).  
1.1.4 Diagnostic tools for diagnosing HHV-6 infection in the CNS 
The presence of HHV-6 DNA in the CSF is highly specific for the diagnosis of HHV-6 CNS infection 
(Sauerbrei and Wutzler, 2002). In HHV-6 CNS infections the levels of the virus are low, and it is 
recommended that a quantitative real-time PCR should be used to detect HHV-6 DNA from the CSF 
(Aberle and Puchhammer-Stockl, 2002, Rotola et al., 2004, Gaeta et al., 2009). The genome of the 
virus is only detectable during the first few days of infection (Linde et al., 1997). Therefore, even 
though the DNA detection is a highly specific method, the negative result does not exclude an 
ongoing infection (Sauerbrei and Wutzler, 2002). The method may also have problems in 
distinguishing CIHHV-6 from a true infection (Caserta et al., 2010). 
Virus-specific IgG antibodies, that are present in the serum and the CSF, can be detected with 
different methods (eg. enzyme-linked immunosorbent assay (ELISA) and immunofluorescent assay 
(IFA)). In HHV-6 CNS infections, as in other human herpesvirus CNS infections, intrathecally 
produced IgG antibodies are detectable in the post-acute stage of the infection (mainly from 10 to 




1.1.5 HHV-6 and demyelinating diseases 
HHV-6 has characteristics that make it highly capable of causing chronic neurological diseases; it has 
high prevalence worldwide, latent nature, ability to re-activate, and opportunistic features. It is a 
highly neurotropic virus and has the capability to penetrate into the CNS, where it stays in a latent 
form and is able to re-activate if the immune system is compromised (Moore and Wolfson, 2002, 
Luppi et al., 1994). HHV-6 infection can cause CNS demyelination and loss of astrocytes (Drobyski et 
al., 1994, Novoa et al., 1997).  
HHV-6 was first associated with MS in 1995, when it was found in the postmortem brains of patients 
that were earlier diagnosed with MS (Challoner et al., 1995). Many studies with brain specimens 
from autopsies have been carried out since then; HHV-6 infection has been seen in demyelination 
areas of CNS tissue samples (Carrigan and Knox, 1997). The patients had colonies of HHV-6-infected 
oligodendrocytes in the white matter of the brain even without histological signs of inflammation 
or demyelination (Challoner et al., 1995, Friedman et al., 1999). HHV-6 has also been found in 
postmortem studies in active as well as inactive MS plaques (Cermelli et al., 2003, Virtanen et al., 
2005). In addition to postmortem findings, HHV-6 has also been found during the early stages of 
acute MS plaques in biopsy specimens of the white matter of living patients (Goodman et al., 2003). 
When autopsy and biopsy specimens are studied, there is a possibility of contamination with body 
fluids. When this occurs, HHV-6 may accidentally enter the specimen and cause a false positive 
result.  
In most postmortem studies, patients have had an MS diagnosis for a long time and the disease has 
progressed for many years. As a consequence, the studies give a comprehensive overview of late 
MS. Studies on serum and CSF samples of patients with early MS give another perspective and an 
opportunity to compare different disease stages. Serum and CSF samples also enable the diagnosis 
of ongoing infections. HHV-6 antibodies are often present in early MS (Villoslada et al., 2003). In 
general, patients with different stages of MS have often HHV-6 DNA in the CSF, especially HHV-6A 
DNA (Knox et al., 2000, Mancuso et al., 2010, Alvarez-Lafuente et al., 2002, Ablashi et al., 2000, 
Alvarez-Lafuente et al., 2008, Rotola et al., 2004). In other studies, active viral replication of HHV-6 
was discovered during the clinical episodes of relapsing-remitting MS (RRMS) patients (Alvarez-
Lafuente et al., 2004, Alvarez-Lafuente et al., 2007). In addition, patients with MS and active HHV-6 




increase of HHV-6 antibodies was connected with RRMS episodes (Simpson et al., 2012, Behzad-
Behbahani et al., 2011). An active HHV-6 infection or re-activation is related to MS disease activity 
in RRMS and secondary progressive MS (SPMS) (Chapenko et al., 2003). 
Even though many studies on MS and HHV-6 have been carried out, the association between HHV-
6 with demyelinating diseases remains controversial. Several original studies and reviews suggest 
that there is no relation between MS and HHV-6 infection or re-activation (Hon et al., 2014, Ahram 
et al., 2009, Swanborg et al., 2002, de Villiers et al., 2006, Taus et al., 2000). Some studies have 
found no detectable HHV-6 DNA in the CSF or the serum of patients with MS (Gustafsson et al., 
2013a, Mirandola et al., 1999). There are also studies and reviews that do not exclude the possibility 
that a relation between HHV-6 and MS exist, but statistical significance is lacking or there is no clear 
relation (Voumvourakis et al., 2010, Kuusisto et al., 2008, Ben Fredj et al., 2012, Simpson et al., 2014, 
Ben-Fredj et al., 2013, Swanborg et al., 2003, Al-Shammari et al., 2003, Enbom et al., 1999). The 
heterogeneity of the MS disease together with the variability in diagnostic methodology for HHV-6 
imposes challenges for the research.   
1.1.6 HHV-6 in other neurological diseases 
HHV-6 is known to cause febrile illness and seizures, especially in childhood (Laina et al., 2010). It is 
capable of causing encephalitis and encephalomyelitis in immunocompromised (Seeley et al., 2007, 
Baldwin, 2011), as well as immunocompetent patients (Yao et al., 2009, Denes et al., 2004, Isaacson 
et al., 2005, Pot et al., 2008). Encephalitis may occur with or without the typical skin rash (Yamamoto 
et al., 2015), and it may have an epileptic onset; also in adults (Merelli et al., 1996). 
In some reports, HHV-6 has been linked to chronic fatigue syndrome (CFS) (Ablashi et al., 2000, 
Komaroff, 2006). HHV-6 antigens have been found in glioma and other brain tumor samples 
suggesting possible involvement in the pathogenesis of CNS malignancies (Chi et al., 2012, Stodberg 
et al., 2002). HHV-6 has been reported to cause meningoradiculitis in previously healthy adults 
(Karam et al., 2009). HHV-6 can cause retrobulbar optic neuritis in HIV-infected patients (Mechai et 
al., 2007). It has caused optic neuritis to previously healthy adults as well (Moschettini et al., 2006). 




HHV-6 has also been found in the CNS of patients with Alzheimer’s disease and with Parkinson’s 
disease (Hemling et al., 2003). On the other hand, it was reported that in both of the diagnosed 
groups, as well as the reference group, more than three-quarters of the patients had HHV-6 DNA in 
their brain specimen. This relation was equal in all patient groups, which demonstrates the 
commonness of HHV-6 in the CNS (Hemling et al., 2003). 
 
1.1.7 Antiviral treatment of HHV-6 
There are no large clinical studies on antiviral treatments of HHV-6 infected adults. Most of the 
knowledge is based on the results of cell cultures, as well as successful and unsuccessful treatments 
from small cohorts. Ganciclovir, valganciclovir, cidofovir, and foscarnet are known to be effective 
antivirals against HHV-6 CNS-infections, and experience is mainly gained from monotherapy and 
antiviral drug combinations (Table 1).  
In cell cultures, foscarnet and ganciclovir are known to inhibit the replication of HHV-6 in human 
lymphocytes (Akhyani et al., 2006). Foscarnet also effectively inhibits the replication of HHV-6 in 
neural glial cells (Akhyani et al., 2006). 
Acyclovir is not recommended because it has an antiviral effect towards HHV-6 mainly in toxic levels 
(Manichanh et al., 2000). Valaciclovir has no effect on the presence of HHV-6 DNA in the blood or 
saliva (Hollsberg et al., 2005). There are successful experiences when treating immunocompetent 
patients, who have HHV-6 infections with other than CNS disorders, with antivirals (e.g. acute liver 





Table 1. Reports of HHV-6 infected adult patients successfully treated with antiviral medication. The 
main problems (myelosuppression or nephrotoxicity) with the medications are collected from the 
official instructions made by the pharmaceutical companies and were also discussed in the studies 
referenced. 















Cymevene®  5-10mg 
/kg/day 
(i.v.) 
Hirabayashi et al., 2013,  
Zerr et al., 2002,  
Mookerjee and Vogelsang, 
1997, 
Tokimasa et al., 2002 
Ljungman et al., 2007  
Denes et al., 2004 
Moschettini et al., 2006  
Troy et al., 2008 
myelosuppression  
HHV-6 may have 
resistance:  














Vu et al., 2007,  
Baldwin, 2011,  
Cole et al., 1998  
Pohlmann et al., 2007 
Pantry et al., 2013 nephrotoxicity 
Valganciclovir 




 Karam et al., 2009 
Isaacson et al., 2005 
Pantry et al., 2013  
Watt et al., 2012 
myelosuppression 
*Reported successful experiences when treating HHV-6 -related CNS disorders of 
immunosuppressed or immunocompetent patients 
 
1.1.8 Radiological features in HHV-6 encephalopathy  
In HHV-6 CNS infections, a CT performed during the early phases of HHV-6 infection is usually normal 
(Noguchi et al., 2010). Typical MRI findings are transient signal intensity abnormalities in the mesial 
(hippocampus, amygdala) and temporal lobes (Noguchi et al., 2010, Provenzale et al., 2008).  
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1.2 VARICELLA-ZOSTER VIRUS 
1.2.1 Introduction and characteristic features of the virus 
VZV is an alpha-herpesvirus that has a high seroprevalence (>95%) in adults in western countries 
(van Lier et al., 2013, Lee et al., 2013, Salleras et al., 2008). The primary infection usually occurs in 
childhood between two and six years of age and its clinical manifestation is chicken pox (van Lier et 
al., 2013). Its typical features are fever with skin vesicles of various stages all over the body (Figures 
2 and 3). The incubation period usually ranges from 10 to 21 days. The virus becomes infectious two 
days before the vesicles appear, and continues to be infectious until the last vesicles have broken 
down and formed granulation.  
VZV also has neurotropic characteristics, and after the primary infection it remains in a latent form 
in the human host. Latency sites include predominantly the neurons in dorsal root ganglia, cranial 
nerve ganglia, and autonomic ganglia along entire neuraxis (Gilden et al., 2014, Nagel et al., 2014). 
VZV can reactivate when the immune system is compromised. A typical clinical feature of re-
activation is herpes zoster (shingles). It includes a typical skin rash and pain within 1-3 dermatomes 
(Figures 4 and 5).  
VZV can also cause CNS complications (e.g. meningitis, encephalitis, and acute disseminated 
encephalomyelitis (ADEM)) that may be fatal (Pahud et al., 2011, Science et al., 2014).  CNS-related 
symptoms may vary from persistent hiccups and vomiting up to generalized seizures (Science et al., 





Figure 2. Chicken pox with a typical rash in a two-year-old child. (Photograph is published with the 
permission of Lotta Palmén and with the permission of the parents.) 
 
    




Figure 4. Herpes zoster in the thoracic area. (Photograph is authors own material) 
 




1.2.2 Clinical significance in adults 
The VZV primary infection in adulthood is usually more severe when compared to the primary 
infection that occurs in childhood. In adulthood the disease is more often related with complications 
and patients might even need hospitalization (Malavige et al., 2008).  
VZV may re-activate if the immune system is somehow compromised, but it may cause CNS 
complications even in immunocompetent adults (Sanguankeo et al., 2015, Pasedag et al., 2014, 
Nandhagopal et al., 2014, Halling et al., 2014, Klein et al., 2010). Besides herpes zoster and zoster 
sine herpete, VZV re-activations may cause a variety of neurological and ocular diseases in adults, 
including meningoradiculitis, cerebellitis, myelopathy, and VZV-vasculopathy (Nagel and Gilden, 
2014). Vasculopathy may occur in central or peripheral arteries (Srivastava and Nagpal, 2014).  
CNS complications are usually re-activations and they may occur either without a characteristic rash 
or a delayed rash (Pahud et al., 2011, Sanguankeo et al., 2015). Typical symptoms in VZV CNS 
infections are headache, fever, and neck stiffness (Becerra et al., 2013). Typical signs of a virus 
infection have been, however, lacking in approximately half of the cases; patients have lacked 
typical VZV rash, fever, or even systemic inflammation markers such as CRP and mean leukocyte 
count (Becerra et al., 2013).  
1.2.3 Diagnostic tools for diagnosing VZV infection in CNS 
In VZV CNS infections, CSF analyses are the main useful tools in diagnostics. Most adolescents and 
adults have VZV-serum-antibodies as a sign of an earlier VZV infection, and therefore serum-
antibody detection alone is not useful in diagnosis of CNS infections. VZV DNA detection from the 
CSF is a highly specific and sensitive method in diagnosing VZV CNS infections (Kleinschmidt-
DeMasters and Gilden, 2001). In some cases, however, DNA detection may remain negative even if 
the patient has a clinical VZV CNS infection (Fox et al., 2001). In these cases, a VZV antibody 
detection from CSF may confirm the diagnosis (Fox et al., 2001). There are a few known reasons why 
DNA detection or antibody production may give a false negative result in VZV CNS infections. In 
some cases of VZV CNS infections, some active viral replication may occur in the cerebral arteries, 
and therefore the virus is not present in the brain parenchyma (Morita et al., 2003). In addition, if 
the antiviral treatment has been started early, the DNA may not be detectable. 
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If effective antivirals are started early, they may delay or, in some minority of cases, even prevent 
antibody production (Linde et al., 1997).  
1.2.4 VZV and demyelinating diseases 
The relation between VZV and MS is controversial. Many studies have found some possible 
association between VZV and MS pathogenesis or the disease course (Ross et al., 1995, Perez-Cesari 
et al., 2005). Many studies, however, also suggest that no association exists between VZV and MS 
(Burgoon et al., 2009, Marrie and Wolfson, 2001, Myhr et al., 1998, Lenman and Peters, 1969). 
VZV has characteristics that make it potent to cause or trigger MS disease: it is neurotropic, 
distributed worldwide, and stays in latent form in human host. VZV seems to have increased 
incidence in both childhood and early adulthood which coincides with MS incidence (Puchhammer-
Stockl et al., 2012). VZV seems to be able to cause demyelination in CNS (Hausler et al., 2002). It is 
also capable of causing recurring episodic neurological infections in immunocompetent patients, 
which matches the disease course of RRMS (Haug et al., 2010).  
It has been reported that patients with a VZV infection have also had signs of demyelination in MRI 
of the brain (Koskiniemi et al., 2002). A history with VZV infection has been associated with a higher 
risk for developing MS (Rodriguez-Violante et al., 2009, Ross, 1998). A herpes zoster episode seems 
to increase the risk of developing MS (Kang et al., 2011). VZV DNA was present in the CSF of patients 
who were diagnosed with MS, and with most of the patients the DNA was present mainly during 
their relapses (Sotelo et al., 2008, Ordonez et al., 2010, Mancuso et al., 2007, Sotelo et al., 2014). 
During MS relapses, VZV DNA was present in the patients’ serums as well (Sotelo et al., 2007). 
1.2.5 Antiviral treatment and prevention of VZV  
The primary infection of VZV in immunocompetent children usually has a benign disease course and 
needs no antiviral medication. The most common clinical form of re-activation in 
immunocompetent adults, herpes zoster, is usually benign as well. It is self-limited, and antiviral 
medication may not be needed. If the patient is immunocompromised or has some VZV 
complications, including CNS involvements, antiviral medication is needed (Lionnet et al., 1996). 




(Arvin, 1996). Acyclovir is the safest of the VZV antivirals and is therefore the most used, especially 
in VZV CNS infections (Lionnet et al., 1996).  
There is an effective prevention for VZV infection: live attenuated varicella-zoster virus vaccine.  
Despite being VZV-vaccinated, patients may have a varicella breakout even with neurological 
complications (Aslan et al., 2014). It is thought that VZV in a vaccine can induce optic neuritis. The  
mechanism for vaccine-VZV induced type of optic neuritis is different from the mechanism involved 
in other post-vaccination optic neuritides (Han et al., 2014). The VZV type used in VZV vaccine may 
also form a state of latency and, in rare cases, cause clinical re-activation (Tseng et al., 2014). Herpes 
zoster can be prevented with a vaccine that contains live attenuated varicella-zoster virus. The 
vaccine was licensed in 2006 and is indicated only for adults. With the vaccination the risk of 
developing herpes zoster is significantly reduced (Lal et al., 2015).  
 
1.3 MULTIPLE SCLEROSIS  
1.3.1 Introduction and clinical characteristics of MS 
Multiple sclerosis is a demyelinating disease that usually affects young adults. Patients are typically 
previously healthy, more often female than male, and in their thirties.  
The incidence of MS has slightly increased in Finland during the last decades and, according to 
different studies, it varies from 6 to 9 /100000/year (Krokki et al., 2011, Sumelahti et al., 2014). The 
prevalence in Finland is approximately 103 /100000 and varies notably in different parts of the 
country (Krokki et al., 2011). 
The diagnosis is based on clinical guidelines that have been revised several times, because the 
clinical diagnostic tools have continuously developed and improved (MRI imaging, laboratory 
diagnostics). The very first characterization of MS was made in 1868 by Charcot (Landtblom et al., 
2010, Poser and Brinar, 2004). In 1931, Allison was the first who divided MS into four different 
categories and later, in 1954, Allison and Millar together rearranged MS into three categories: early, 
probable, and possible MS (Poser and Brinar, 2004). The first actual criteria to diagnose clinically-
definite MS was created in 1961 and called “the Schumacher criteria” (Poser and Brinar, 2004). In 
1980, Bauer was the first who included CSF OCBs in MS criteria and later, in 1983, MRI was also 
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partly included in the new and more detailed guideline “the Poser criteria” (Poser and Brinar, 2004). 
Many other revisions and recommendations were also made for each of the characterizations and 
guidelines. The latest international guideline is based on the criteria of McDonald and was first 
presented in 2001 and also characterized PPMS (McDonald et al., 2001). The latest generally 
accepted revision for the McDonald criteria was made in 2010 (Polman et al., 2011).  
MS is a disease with a wide variety of different clinical characteristics, and it is described to be more 
like a syndrome than just a disease (Barnett et al., 2009). There are three common clinical 
approaches for the different types of disease courses of MS. The different forms of MS are briefly 
presented below.  
The most common form of MS has a disease course with clinical episodes called relapses that are 
followed with remission stages; relapsing-remitting multiple sclerosis. In Finland, 89% of the MS 
diagnoses are RRMSs (Sumelahti et al., 2014). The neurological symptoms depend on the location 
of the inflammatory demyelination in the CNS. Symptoms may be motor or sensory deficiencies, 
typically unilateral (i.e. weakness, spasticity, paresthesia). The patient may have optic neuritis or 
diplopia.  In some patients, symptoms may include vertigo and problems in controlling the urinary 
or gastro-intestinal -system. Some patients may also report exceptional fatigue as a symptom. 
According to the definition, an episode lasts from a minimum of 24 hours to a maximum of 4 weeks 
(Poser et al., 1983, McDonald et al., 2001). The episode includes either new symptoms from a 
different CNS region or clear and rapid exacerbation of earlier symptoms. In most cases, symptoms 
are transient, but some residual symptoms may remain.  
RRMS can be diagnosed based on the 2010 revised McDonald criteria (Polman et al., 2011): I) If the 
patient has had two or more clear distinct episodes (more than 30 days between the episodes) from 
different CNS regions, at least one of them clinically confirmed, and if the patient has two or more 
lesions with objective clinical evidence in the MRI, the MS diagnosis is confirmed. II) If the patient 
has had two episodes, but only one lesion with objective clinical evidence, the dissemination in 
space should be demonstrated before MS can be diagnosed. III) If the patient has had only one 
episode and has two or more lesions with objective clinical evidence in MRI, the dissemination in 
time should be demonstrated before MS can be diagnosed. In Finland, lumbar puncture sampling is 
still highly recommended in order to distinguish other inflammatory or infectious diseases from MS. 




diagnosis. Also elevated IgG index, that indicates the amount of IgG in CSF compared to amount of 
IgG in serum, is seen in 70-80% of patients with MS (Andersson et al., 1994). 
If a patient has had only one episode and only one lesion with objective clinical evidence, the disease 
is classified as clinically isolated syndrome (CIS) (Polman et al., 2011). These patients have a higher 
risk for their disease to progress into MS and in Finland it is recommended to routinely control the 
clinical neurological condition and perform an MRI 3-12 months after the classification of CIS (based 
on Finnish Current Care Guideline, updated 3.12.14).  
In Finland, 11% of MS diagnoses are classified as primary progressive (PPMS) types (Sumelahti et al., 
2014). Patients with PPMS do not typically have distinguishable episodes, but the disease and the 
disability of the patient progress continuously. PPMS can be diagnosed based on the McDonald 
criteria revised in 2010 (Polman et al., 2011): If the patient has had a disease progression for a year 
or longer and has two of the following criteria: evidence for the dissemination in space either I) in 
the brain or II) in the spinal cord or III) a positive CSF finding with an elevated IgG index or OCBs.  
When the daily disability of the patient in RRMS type of disease course starts to worsen between 
relapses or without relapses, the disease has progressed to a secondary progressive multiple 
sclerosis (SPMS).  
If the patient has typical MS lesions in MRI but no clinical symptoms of CIS or MS, the condition is 
called “radiologically isolated syndrome” (RIS). It is usually a coincidental finding, when the patient 
has undergone MRI imaging for another reason than a suspicion of demyelination. Approximately 
30% of the patients with RIS seem to have neurological episodes and some of these progress into 
CIS or MS within five years (Granberg et al., 2013, Okuda et al., 2014). In Finland, patients with RIS 
are not recommended to have specific routine controls.  
1.3.2 Pathogenesis of MS 
Environmental factors, genetic predisposition, and infective factors, similar to other autoimmune 
diseases, play a role in MS pathogenesis (Karussis, 2014). The main pathological event is the 
destruction of myelin in the CNS, but also neurons are damaged depending on the stage of the 
disease course. During the early stages of MS oligodendrocytes and myelin sheaths in the lesions 
are destroyed but axons and neurons remain mainly uninjured (Lucchinetti et al., 2011). The MS 
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plaque is not in a static state (Wu and Alvarez, 2011). A single active MS plaque in the CNS contains 
complex morphological features that depend on disease duration (Barnett et al., 2009). The disease 
mechanisms also differ among the natural disease courses of MS (Lassmann, 2013). Even the target 
antigens seem to vary in the disease progression (Sellebjerg et al., 2000). 
1.3.2.1 Cell-mediated autoimmunity theory of MS 
Different T cells are thought to be the main agents in the cell-mediated autoimmune reaction in MS 
pathogenesis. In particular, CD4+ T cells have a role in both cell-mediated and in humoral 
autoimmune reactions. These CD4+ T cells may incorrectly identify an auto-antigen and lead to an 
attack against the host’s own myelin in the CNS and cause demyelination. A few auto-antigens are 
known, which these T cells recognize: myelin basic protein (MBP), myelin oligodendrocyte 
glycoprotein (MOG), myelin-associated glycoprotein, and proteolipid protein (PLP). These auto-
antigenic T cells are found in patients with MS and in reference controls as well, and it is thought 
that in MS disease some agent incorrectly activates these T cells (Hellings et al., 2001). Autoreactive 
CD8+ T cells are also found in both patients with MS and reference controls, but they may differ in 
targets that activate them (Berthelot et al., 2008). Regulatory T cells (Treg) control host auto-
antigenic T cells and their defective function is seen in patients with MS (Costantino et al., 2008). In 
addition, apoptosis of incorrectly-activated auto-reactive T cells is not activated properly or is 
actively inhibited in patients with MS, which is thought to be another mechanism for demyelination 
in the CNS (Moreno et al., 2014, Sharief, 2000, Saresella et al., 2005, Sharief and Semra, 2001).  
1.3.2.2 Humoral autoimmunity theory of MS 
The cells in the humoral immune system are also thought to be associated with MS pathogenesis.  
Naïve CD4+ cells are activated by dendritic cells (DCs) that serve as antigen-presenting cells in the 
immune system. In MS, these DCs occur in activated phenotypes (Grigoriadis and van Pesch, 2015, 
Xie et al., 2015). CD4+ T-helper cells can also incorrectly recognize auto-antigen, either 
spontaneously or by activation of auto-antigen-specific B cells (Harp et al., 2010). The activated T-
helper cell then incorrectly activates other B cells to attack against the host’s CNS. CNS-specific B-
cells have been found from patients with MS (Kuerten et al., 2014).  
B cells migrate from peripheral blood into the CNS through the blood-brain-barrier (BBB) and 




seen as OCBs (Bankoti et al., 2014, von Budingen et al., 2010). MS lesions with clear demyelination 
and astrocytosis contain high amounts of IgG (Glynn et al., 1982). Antibodies signal macrophages to 
incorrectly cause host myelin destruction. Active MS plaques are known to contain myelin-laden or 
foamy macrophages, indicating ongoing demyelination (Lucchinetti et al., 2011).  
B cells seem to have a strong role in the immunopathogenesis of MS. Besides the ability of B cells to 
activate T cells, their presence affects proliferation of the T cells (reduces when are not present) 
(Bar-Or et al., 2010). Virus-specific B cells are also capable of becoming active without the help of T 
cells (Hebeis et al., 2004).   
1.3.2.3 Viral theories of MS pathogenesis 
During the past decades, numerous different viruses have been proposed to be involved in MS 
pathogenesis. In the 1970s, the measles was strongly associated with MS (Salmi et al., 1972). Other 
candidates included HSV (Fraser et al., 1972) and an MS-associated agent, also called “Carp agent” 
(Carp et al., 1972, Koldovsky et al., 1975). In the 1980s, on the other hand, EBV was associated with 
MS and still is the strongest candidate to date (Belbasis et al., 2015). A new retrovirus was also found 
at this time, which was soon connected with MS as well (Greenberg et al., 1989, Perron et al., 1997). 
Different viruses are thought to be able to cause demyelination in both the cell-mediated and 
humoral immune pathways. Viruses may activate B cells to produce cross-reacting antibodies  or 
they may activate T cells (with molecular mimicry) to destroy host oligodendrocytes (Venkatesan 
and Johnson, 2014). For example, EBV-reactive CD8+ T cells are intrathecally enriched in some of 
the patients with MS and these cells also show increased cytolytic activity against EBV (Lossius et 
al., 2014). The death of oligodendrocytes, that eventually leads to CNS demyelination, may also 
occur via direct virus infection in oligodendrocytes that induces lysis or apoptosis of the cells 
(Venkatesan and Johnson, 2014).  
1.3.3 Treatment of MS 
There is no curative medication to treat MS so far. It is, however, possible to slow down the disease 
progression and reduce the relapses with anti-inflammatory drugs. Most of the new and effective 
drugs against MS relapses have an impact on leucocyte function and reduce their number. Different 
drugs against RRMS are briefly presented in Table 2. 
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Table 2. Immunotherapies used in RRMS treatment in Finland (based on Current Care Guidelines in 
Finland, Käypä hoito, updated 3.12.2014) 
Immunomodulator Target Mechanism of action Reference 
    
Beta-interferon 1a, 1b Binds to type-1 IFN 
receptor on the cell 
surface 
Prevents lymphocyte traffic 
through blood-brain barrier, 
inhibits T cell function, 
modifies the differentiation 
of T cells 
Dhib-Jalbut and 
Marks, 2010, 
Kalinke and Prinz, 
2012 
Glatirameracetate Synthetic polypeptide 
with similarity to 
myelin basic protein 
Prevents the action of        







Prevents the proliferation 
of lymphocytes 
Bar-Or et al., 
2014 




effect and reduces the 
effects of oxidative stress 
Gold et al., 2012, 
Viglietta et al., 
2015 




Prevents lymphocyte traffic 
into the CNS 
Krumbholz et al., 
2012 
Fingolimod Sphinosine              
1-phosphate receptor 
modulator 
Prevents lymphocyte traffic 
from the lymph nodes 
Cohen et al., 2010 
Alemtuzumab Humanized anti-CD52 
monoclonal antibody 
Decreases number of CD52-
expessing cells (some of the 
B and T cells and 
monocytes) from the 
circulation 







1.4 OLIGOCLONAL BANDS  
1.4.1 Introduction of OCBs 
The most important OCBs are IgG class antibodies that are produced in the CSF by clonally expanded 
plasma cells (von Budingen et al., 2010). Isoelectric focusing (IEF) is well established in clinical use 
for detecting OCBs. The main benefit of IEF is its higher sensitivity, when compared to other 
methods (Mygland et al., 2007). If a patient has two or more visible bands in the CSF, the OCB result 
is defined to be positive (Figure 6). True IgG-OCBs that are counted as bands in patients with MS, 




Figure 6.   IEF gel after an IEF run and immunofixation. Serum (n) and CSF (n’) samples are 
compared and clear bands that are seen in CSF and not in serum are defined as positive OCB findings 





1.4.2 OCBs in clinical use 
More than 95% of the patients with MS have OCBs in their CSF (Andersson et al., 1994). OCBs are 
not specific to MS and they can also be seen in other neurological conditions. Even though OCB 
status is no longer required in MS diagnosis, the presence of OCBs remains an important part for an  
MS diagnosis and OCB positivity has predictive value for CIS patients’ disease progressing into MS 
(Dobson et al., 2013, Paolino et al., 1996, Zipoli et al., 2009). It has even been recommended that if 
a patient with MS has no OCB in the CSF, it is in most cases a possible sign of a misdiagnosis of MS 
(Dobson et al., 2013, Zeman et al., 1996).  
1.4.3 OCBs in neurological diseases 
The presence of CSF-specific OCBs is related to immunological reactions in the CNS. Besides MS, 
OCBs may also be present in some patients with other different autoimmune diseases with 
neurological involvements (e.g. systemic lupus erythematosus, Sjögren’s syndrome, 
neurosarcoidosis) and also in some patients with neurodegenerative diseases (e.g. Alzheimer’s 
disease and other dementias) (Petzold, 2013, McLean et al., 1995, Janssen et al., 2004). Few OCBs 
have been found in patients with postencephalitic Parkinsonism (Williams et al., 1979). OCB 
positivity has even been observed in some patients who have had a stroke (Pruss et al., 2012). It is 
thought that some immunological exposure may be related to the pathogenesis of these kinds of 
strokes. OCBs have also been observed in structural central nervous system lesions and in spinal 
arteriovenous malformations with no signs of any CNS infections (Cohen et al., 2000). 
The prevalence of OCBs in the CSF of patients with MS differs worldwide (e.g. in China only 63% of 
patients had a positive OCB result), and it is thought to be dependent on different immunogenetic 
backgrounds (Li et al., 2007). In different countries the OCB status seems to give a different 
prognosis; in a Turkish study, OCB positivity, unlike in other studies, was associated with a better 
prognosis with better result in Expanded Disability Status Scale (EDSS, scale that quantifies disability 
in multiple sclerosis), better clinical course with lower relapse severity (Idiman et al., 2009). In 
another study, OCB status did not seem to be associated with the clinical progress in MS patients 
(Lourenco et al., 2013). OCB positivity is also associated with increased white matter lesions in MS 




et al., 2014). In addition, it has been reported that no relation has been found between the OCB 
status and the number of lesions or the pathology in the CNS (Ellidag et al., 2013).  
It is known that, in rare cases, some MS patients truly lack OCBs.  These patients are thought to have 
more of a benign disease course (Zeman et al., 1996, Lechner-Scott et al., 2012, Joseph et al., 2009, 
Sa et al., 2005). OCB-negative patients seemed to have a different immunogenetic background and 
they may form a subgroup within MS disease (Fukazawa et al., 1998). 
OCBs are also seen in different neurological infections, where they are often produced against the 
infectious agent (e.g. measles in subacute sclerosing panencephalitis) (Vandvik and Norrby, 1973) 
(Table 3).   
1.4.4 OCBs reactivity against different pathogens  
OCB reactivity has been found not only against different CNS virus infections, but also against other 
viruses and Chlamydia pneumoniae, also in MS (table 3).   
Table 3. OCBs reactivity against different pathogens in different diseases 
Pathogen Disease References 
VZV Vasculopathy Burgoon et al., 2003, Luxton et al., 1995, 
Vartdal and Vandvik, 1983 
EBV MS Franciotta et al., 2011, Virtanen et al., 
2014, Rand et al., 2000, Castellazzi et al., 
2014 
Measles Subacute sclerosing 
panencephalitis 
Vandvik and Norrby, 1973, Mehta et al., 




MS Franciotta et al., 2005, Yao et al., 2001 




2 AIMS OF THE STUDY 
 
The general objective of this doctoral study was to investigate the possible role of viruses in MS 
pathogenesis. The aim was to focus on HHV-6A, HHV-6B, and VZV -antibodies and their possible 
presence during the early stages of MS disease.  
The specific aims in each study were: 
 To study clinical data of patients who have had a serologically confirmed acute HHV-
6 infection and investigate their possible signs of MS. (I)  
 To study if OCBs in the CSF contain antibodies that react with HHV-6A or HHV-6B 
antigens in patients with early stage MS or other demyelinating diseases. (II) 
 To study if OCBs in the CSF contain antibodies that react with VZV antigens in patients 
with early stage MS or other demyelinating diseases. (V) 
 To study if patients, who have HHV-6A, HHV-6B or VZV -reactive OCBs in their CSF, 
have some identifiable features including clinical differences, or difference in 





3 PATIENTS AND METHODS 
3.1 PATIENTS  
3.1.1 Patients (I-V) 
(I) Patients were included in this study from an earlier study of serological survey of patients 
with MS. The study design and procedure of patient collection are described in the original 
study (Virtanen et al., 2007a). All patients who had serologically confirmed acute or chronic 
HHV-6A infection (N=9) were selected for detailed evaluation of their clinical data. Eventually 
twelve patients underwent retrospective evaluation of previous clinical data of their 
neurological history. Three patients with other neurological diseases were controls.  
(II-V) All the patients who had OCBs in their CSF and were referred by general practitioners 
for a neurological evaluation, to the Department of Neurology at the University Hospital of 
Helsinki, had serum and CSF samples saved for further retrospective analysis. Systematic 
collection of all the paired serum and CSF samples lasted 365 days. During the collection 
period, altogether 109 patients had a positive result for CSF OCB detection. Samples of 30 
patients with positive results in OCB detection were missing and not available for further 
analysis. All the samplings were clinically indicated because patients had symptoms that led 
to a suspicion of an inflammatory disease of the CNS. Every patient who had a suspicion of 
demyelinating or inflammatory disease (at the Department of Neurology, University Hospital 
of Helsinki) underwent lumbar puncture sampling, according to the protocol of the clinic. 
Every patient diagnosed with MS was treated based on the Current Care Guidelines used in 
Finland. 
3.1.2 Samples (I-V) 
From all our studied patients, both serum and the CSF samples were collected at the same 
time at the beginning of the follow-up. None of the patients had corticosteroid treatment 
prior to lumbar puncture sampling. None of the patients had any immunotherapy (Table 2) 
before the lumbar puncture. Routine clinical tests of CSF (IgG index, protein concentration, 
white blood cells (WBC) and red blood cells (RBC) counting, glucose level, albumin level) 
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were analyzed soon after sampling. Samples were stored at -70 degrees before further HHV-
6 or VZV analysis.  
3.1.3 Ethical approval 





3.2.1 Antibody tests of HHV-6A and HHV-6B (I-IV) 
Immunofluorescence assay (IFA) was used to analyse the level of antibodies in the serum. 
Specific antigens used in IFA analysis were HHV-6A strain GS that was grown in HSB-2 T cell 
line and HHV-6B strain Z29 that was grown in MOLT-3 T-cell line. Serum samples were diluted 
and organized in reciprocal series. The mildest dilution that gave clear green fluorescence 
light above negative control was determined to be the titer. (Virtanen et al., 2007b) 
3.2.2 Avidity test (I-IV) 
Avidity testing was used to determine whether the antibodies of the patient are residues 
from a past infection or from a primary infection, i.e. an ongoing or recent initial infection. 
Avidity tests of IgG antibodies binding capacity to antigen were tested by using urea wash 
(Virtanen et al., 2007b). IgG antibodies with high binding capacity indicate serological past 
infection and antibodies with low binding capacity indicate serological primary infection.  
3.2.3 OCB detection (II-V) 
Paired serum and CSF samples were diluted to the same IgG concentration (usually 20 mg/l). 
The amount of CSF and diluted serum used in this method was 10 μl. IgG antibodies were 




Hydragel 9 CSF isofocusing system on the Sebia Hydrasys Focusing apparatus (Sebia, Lisses, 
France). IgG oligoclonal bands were localized in the CSF by performing immunofixation with 
immunoperoxidase staining. Two or more visible bands in CSF with no serum counterparts 
were determined to be an OCB-positive result. Positive and negative controls were included 
in every series. 
3.2.4 HHV-6 and VZV-reactivity in OCBs (II-V) 
Affinity driven immunoblot was used to localize HHV-6 and VZV -reactive OCBs. 
Nitrocellulose membrane was coated with HHV-6A (Advanced Biotechnologies, Columbia, 
MD) or 6B (Meridian Life Science, Saco, ME) or VZV viral antigens. The VZV antigens were 
provided by the Department of Virology of HUSLAB as a concentrated solution of extracted 
antigens produced by expression in A549 cells. Paired CSF and serum samples of the patients 
were separated by IEF on agarose gel (see “OCB detection” above). The gel was then in direct 
contact overlaid with the nitrocellulose membrane coated with the viral antigen. Passive 
transfer of proteins was performed under pressure of one kilogram for 30 min. Transferred 
IgG bands were then detected with alkaline-phosphatase conjugated anti-human IgG 
(1:1000, DAKO, Glostrup, Denmark) and visualized using 4-nitro blue tetrazolium chloride 
(NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP). Positive and negative controls were 
used in every series. Two or more virus-reactive bands in CSF with no serum counterparts 
were determined to be an OCB-positive result.  
3.2.5 Clinical data (I-V)  
In the clinical evaluation, earlier neurological history of the patients was collected 
retrospectively using a systematic form (in supplements). The clinical evaluation also 
included prior medications and treatments of the patients. Clinical data of neurological 
history contained all the documents that were available for the neurologists who were 
responsible for the examination, diagnosis, and treatment of the patients.  Clinical re-
evaluation was repeated after follow-up time ended.  
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(III-V) Follow-up time lasted a minimum of two years and was started after the end of the 
systematic collection of the samples and neurological diagnoses were re-evaluated 
according to McDonald’s criteria (See 1.3.1 Introduction and clinical characteristics of MS). 
3.2.6 Neurological diagnoses (I-V) 
All the neurological diagnoses were confirmed by a neurologist. All diagnoses were made 
blindly without virus-reactive OCB results. All MS diagnoses were based on current 
guidelines of that time. All the patients whose disease characters fulfilled McDonald’s 
diagnostic criteria were classified as MS. If patients had their first clinically-confirmed 
demyelinating event and their MRI of the CNS didn’t fulfil Barkhof’s criteria (Barkhof et al., 
1997), the disease was classified as clinically isolated syndrome (CIS). All other neurological 
diagnoses were classified to be “other neurological diseases” (OND). 
3.2.7 Statistical analysis (III, V, thesis) 
We used non-parametric Mann-Whitney U test in comparing differences between groups. 
We used PASW Statistics 18 software for calculating statistical tests. All our tests were two-





4 RESULTS  
4.1 HHV-6 SEROLOGICAL PRIMARY INFECTION AND MS   (I, III, IV) 
Of the 23 patients with, serologically-confirmed primary HHV-6A or HHV-6B infection, we found 18 
who had serologically confirmed primary infection during or near the clinically-distinct 
demyelinating event (Table 4). Of those 18 patients, 11 were diagnosed with MS soon after the 
clinical and laboratory investigations (Table 6). None of the patients who had a primary HHV-6 
infection had any typical signs of a virus infection (e.g. fever, rash).  
Patients who had serological primary HHV-6 infections were from 18 to 53 years old (mean 35 
years). Of the patients, 13 were female (57%) and 10 were male (43%). 
Many patients had clear time-dependent relation between HHV-6A/B serological primary infections 
and their clinically-confirmed neurological symptoms of demyelination (Figure 7). There were 
patients with only HHV-6A- (43%, n=10) or only HHV-6B-primary infections (35%, n=8). Five of the 
patients had serological primary infection with both HHV-6A and HHV-6B at the same time (22%, 
n=5). 
Primary HHV-6 infections were also seen in some other neurological diseases, besides MS or CIS: 
one patient was diagnosed with Mollaret’s meningitis and one patient had epilepsy. More detailed 
presentation of patients is in Table 4. 
HHV-6 analysis was made retrospectively for all of the patients and therefore no one received 

















Diagnosis after the      




 F / M 
Time in months 
between latest 
neurological 
symptoms  to 
sampling 
1 6A ADEM ADEM 47 F 1 
2 6A MS MS 33 M 2 
3 6A epilepsy epilepsy 21 F  - 
4 6A MS MS 48 F 2 
5 6A PPMS PPMS 38 M 0 
6 6A MS no follow-up 35 F 3 
7 6A MS no follow-up 27 F 6 
8 6A CIS no follow-up 49 F 3 
9 6A CIS no follow-up 39 F 2 
10 6A CIS no follow-up 36 M  years * 
11 6B tension neck no follow-up 23 M  - 
12 6B depression no follow-up 39 M  - 
13 6B MS MS 39 F 0 
14 6B CIS Mb n.peronei and 48 M 0 
15 6B MS MS 31 F 3 
16 6B CIS/RIS CIS 53 F 4 
17 6B CIS CIS 29 M 0 
18 6B MS MS 48 M years * 
19 6A+6B MS MS 21 F 4 
20 6A+6B MS MS 40 M 0 
21 6A+6B Mollaret’s 
meningitis 
Mollaret’s meningitis 18 M  - 
22 6A+6B MS MS 44 F 0 








female / male 
multiple sclerosis, relapsing-remitting disease course 
CIS clinically isolated syndrome  
ADEM acute disseminated encephalomyelitis 
RA rheumatoid arthritis  
PPMS primary progressive MS  
RIS radiologically isolated syndrome, patient had no clinical episode 





Figure 7.  Diagrams of two patients with primary HHV-6A infections and time-dependency of its 
relation with demyelinating events. One was soon diagnosed with MS and the disease of the other 
one was classified as CIS. (SEP= somatosensory evoked potential, BAEP= brainstem auditory evoked potential, 





4.2 VIRUS-REACTIVE OCBS   (II-V) 
Of 79 patients, altogether 26 (33%) had HHV-6A and/or HHV-6B and/or VZV –reactive OCBs in their 
CSF. Of 17 patients who had HHV-6-reactive OCBs, altogether 35% (n=6) had both HHV-6A and HHV-
6B-reactive bands, 18% (n=3) had only HHV-6A-reactive OCBs, and 30% (n=5) had only HHV-6B 
OCBs. Of 12 patients who had VZV-reactive OCBs, 3 had concurrent HHV-6 –reactive OCBs (Table 5). 
 
Figure 8.   Nitrocellulose membrane with HHV-6A –reactive OCBs. In “HHV-6A pos” contains 
positive control, two columns of negative controls are un-named in the photograph, 
“S” contains serum of the patient, and “L” contains CSF of the patient. In CSF (L) there 
are visible bands that don’t have serum counterparts (S).  (Photograph is authors own 
material) 
Virus-reactive OCBs were present in patients CSF near the event of their clinical neurological 
symptoms that led to a suspicion of demyelinating disease (Table 5). Overall 62% (n=16) of the 
patients were diagnosed with MS soon after the lumbar puncture. The disease of seven patients 
was classified as CIS. 
No significant differences were evident in the clinical courses or symptoms among patients who had 
virus-reactive OCBs in their CSF and patients who had no virus-reactive OCBs. Most of the patients 
with MS, who had virus-reactive OCBs, had relapsing-remitting disease course and only one patient 
had PPMS. During the follow-up time of two years, the diagnosis of one patient progressed from CIS 
to MS, and the diagnosis of one patient was re-classified from MS to CIS. (Table 5)  














Dg after lumbar 
puncture, at the 
beginning of 
follow-up 








1 HHV-6A+6B F 48 4 MS MS 3 
2 HHV-6B F 30 0 MS MS 4 
3 HHV-6A+6B M 32 3 CIS CIS  
4 HHV-6A F 29 3 MS CIS  
5 HHV-6A F 47 4 ADEM ADEM  
6 HHV-6A M 39 4 MS MS 2 
7 HHV-6A+6B F 29 3 MS MS 3 




9 HHV-6A+6B M 31 4 MS MS 1 
10 HHV-6B F 29 0 CIS CIS  
11 HHV-6B F 21 0 MS MS 3 
12 HHV-6B M 40 4 MS MS 4 
13 HHV-6A+6B F 21 3 PPMS PPMS  
14 HHV-6B F 33 1 CIS CIS  
15 VZV M 31 3 CIS CIS  
16 VZV F 49 0 Mollaret’s   
17 VZV F 25 3 MS MS 2 
18 VZV F 37 1 CIS CIS  
19 VZV F 32 4 MS MS 1 
20 VZV M 44 3 CIS CIS  
21 VZV M 31 4 MS MS 1 
22 VZV F 39 0 CIS MS 1 
23 VZV F 35 2 MS MS 4 
24 HHV-6A+VZV F 29 3 MS MS 2 
25 HHV-6A+6B+VZV F 25 4 MS MS 3 
26 HHV-6A+6B+VZV F 16 3 MS MS 3 
 
Patients with HHV-6 or VZV-reactive OCBs had significantly higher IgG index (p=0.007) and more 
OCBs (p=0.003) in their CSF in comparison to patients with no virus-reactive OCBs in their CSF (Table 
6). Patients with virus-reactive OCBs also had lower protein concentration and they were also 




Table 6. Patients with CIS or MS 
 Virus-reactive No virus- All  Significance of 
  OCB reactive OCB patients difference, p-value* 
All / M / F (n) 23 / 7 / 16 42 / 13 / 29 65 / 20 / 45 NS 
Age (mean) 31 (SD 7.5) 35 (SD 9.1) 34 (SD 8.7) NS 
IgG index1 (mean) 1.37 (SD 0.63) 1.02 (SD 0.50) 1.15 (0.57) 0.007 
MRI, Barkhof x/4 2.5 (SD 1.5) 2.9 (1.3) 2.7 (SD 1.3) NS 
Protein concentration2 (mean) 341 376 363 NS 
WBC count3 (mean) 10 10 10 NS 
No. of all OCBs (mean) 21 (SD 5.4) 16 (SD 6.7) 17 (SD 6.6) 0.003 
*Significance of difference when comparing patients with HHV-6 or VZV-reactive OCBs in their CSF with patients 
who have no virus-reactive OCBs. P-values less than 0.05 were considered statistically significant.  
 
Reference values:     
1 0.34-0.60     
2 150-450 mg/l     
3 0-5 x 106/l 
 
 
     
Of the patients with virus-reactive OCBs, 8 had both HHV-6A and HHV-6B –reactive OCBs in their 




Figure 9.  Patient is a 16-year-old previously-healthy female, who had both HHV-6 and VZV- reactive 
OCBs in her CSF in early MS. (Avonex= Beetainterferon 1a, ACE= Angiotensin-1-converting enzyme, prot= 
protein concentration, S-Borrelia= serum antibodies of Borrelia Burgdorferi, VEP= visual evoked potential, SEP= 
somatosensory evoked potential). 
 
 
We collected differences in several parameters from separate studies (III, V, thesis): between 
patients who had HHV-6 reactive OCBs and who had no HHV-6 reactive OCBs, between patients who 
had VZV-reactive OCBs and who had no VZV-reactive OCBs, and between patients who had HHV-6A 
and / or HHV-6B and /or VZV –reactive OCB and patients who had no virus-reactive OCBs at all. 
Differences were seen in patient age, their number of total OCBs in CSF, amount of protein 
concentration in CSF, and level of IgG index. In separate studies, differences in different parameters 




Table 7. Statistical comparison of the differences in parameters of patients who had HHV-6 or VZV 
–reactive OCBs in their CSF comparing patients who had no HHV-6 or VZV –reactive OCBs. 
Differences are collected from different studies to the same table. Significant p-values (p < 0.05) are 
presented; non-significant (NS).  
 Patients with HHV-6-
reactive OCBs compared 
to patients with no virus-
reactive OCBs 
Patients with VZV-reactive 
OCBs compared to 
patients with no virus-
reactive OCBs 
Patients with both HHV-6-
reactive and/or VZV-
reactive OCBs compared 
to patients with no virus-
reactive OCBs 
Younger age 0.047 NS NS 
More OCBs in CSF 0.001 NS 0.003 
Lower protein 
concentration in CSF 
NS 0.012 NS 





5 DISCUSSION   
5.1 SEROLOGICALLY CONFIRMED HHV-6 IN MS 
Several patients were found with a serological primary infection as a sign of an active HHV-6 
infection in early MS. This agrees with earlier studies, where some of the patients with MS seem to 
have a systemic HHV-6 infection or activation seen as a presence of active antibodies or HHV-6 DNA 
in the serum (Akhyani et al., 2000, Caselli et al., 2002, Berti et al., 2002, Friedman et al., 1999, 
Tomsone et al., 2001). Systemic activation of HHV-6 or infection by HHV-6 in MS is controversial and 
in some studies there are no signs of an active HHV-6 infection in peripheral blood (PB) (Rotola et 
al., 1999).  
In comparison to HHV-6B, HHV-6A is more often associated with MS and other chronic neurological 
diseases, but surprisingly many patients carried HHV-6B-primary infections and some seemed to 
have serological signs of a co-infection. Usually, HHV-6A is known to cause a symptomless primary 
infection shortly after HHV-6B primary infection in childhood (Agut, 2011). It is possible that the 
same pattern of co-infection may also be seen in adulthood.  
One of the weaknesses in our serum-sample study is that there were no previous serum samples 
from the patients’ childhood nor from the time before their neurological symptoms. Such samples 
would have reliably shown if our patients with serologically confirmed primary HHV-6A or HHV-6B 
infections truly lacked HHV-6 antibodies before their neurological symptoms and if this HHV-6 
infection was their first HHV-6 infection. We have no systematic reliable data on the childhood 
infections of the patients because the clinical evaluation was based on a retrospective collection of 
clinical neurological data and the patients had no interviews nor questionnaires about their HHV-6 
infection history. The seroprevalence of HHV-6 is not 100% in adulthood and, therefore, it is possible 
that the serologically confirmed primary HHV-6 infections may be true and not re-activations.   
Even though HHV-6A and HHV-6B are separate viruses, they have been analyzed and discussed 
together in some parts of the study. In both serological and CSF studies, almost half of the HHV-6 
cases were associated with HHV-6A and the rest with HHV-6B. The overall number of HHV-6 cases 
in our studies was too low for further relevant comparison between these viruses, and therefore we 
didn’t separate them. In our study, however, the HHV-6 findings were clearly not associated with 
only one of the viruses.  
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None of the patients had typical signs of an active virus infection (i.e. fever, skin rash). HHV-6 may 
occur without any typical skin rash (Sloots et al., 1995, Yoshikawa et al., 2001). It seems that HHV-6 
may manifest without the typical symptoms of viral CNS infection in immune-competent adults, in 
contrary to immunocompromised patients (Al Fawaz et al., 2014, Astriti et al., 2006). 
In many studies, the focus has been on the detection of viral DNA. It is known that low viral loads 
are often seen in acute CNS infections of herpesviruses (Gaeta et al., 2009). In addition, postmortem 
studies of patients with HHV-6 infections have shown that in some cases a low amount of HHV-6 
DNA is seen in the CSF and a high load of HHV-6 remains in the CNS tissue (Fotheringham et al., 
2007). It is therefore likely that the absence of HHV-6-DNA in patient CSF or serum samples doesn’t 
necessarily exclude an ongoing or recently activated HHV-6 infection. In primary HHV-6 infections 
the DNA load in the CSF is significantly lower than in HHV-6 reactivations, and the pathological 
mechanisms are thought to be different; in reactivation, virus replication in the CNS is more active 
and in primary infection the inflammatory mediators are more involved than straight virus 
replication (Kawamura et al., 2011). It may therefore be useful to perform an assay for the detection 
of HHV-6 antibodies if no HHV-6 DNA is found in the CSF.  
HHV-6 seems to be present in early MS but association does not necessarily mean causation. It is 
possible that HHV-6 primary infection or activation is a consequence rather than a cause in MS 
disease. One hypothesis is that in MS, patients have an overactive immune system that leads to 
polyclonal B cell activation and it explains immune reactivity to many viruses (Dhib-Jalbut et al., 
1990). Polyclonal antibody production may then be seen in the presence of HHV-6 antibodies, as 
well as other viral antibodies. However, in one study, MS patients demonstrated high immune 
reactivity to HHV-6 even when compared to other auto-immune diseases (Friedman et al., 1999). 
This suggests that a pathogenetic role is possible. Moreover, HHV-6 is able to reactivate in MS 
patients treated with natalizumab (Yao et al., 2008) and the active HHV-6 replication can decrease 
the response to certain MS treatments (Garcia-Montojo et al., 2011). Therefore, although HHV-6 is 
hardly the main agent in MS immunopathogenesis, it has to be taken into account in the evaluation 




5.2 VIRUS-REACTIVE OCBS IN MS   
Altogether 26 patients (out of 79) were found to carry HHV-6A and/or HHV-6B and/or VZV –reactive 
OCBs in their CSF near the event of clinical neurological symptoms that lead to a suspicion of a 
demyelinating disease. Most of the patients were soon diagnosed with MS (62%, n=16).  
HHV-6 reactive OCBs have also been reported in a different MS patient cohort using the same 
method (Virtanen et al., 2014) and also in another MS cohort using a different method (Alenda et 
al., 2014).  
Patients with HHV-6 or VZV-reactive OCBs seem to differ statistically in laboratory parameters from 
the patients who have no virus-reactive OCBs in their CSF. They have a significantly higher IgG index 
and more OCBs in their CSF. Patients with virus-reactive OCBs also have lower protein concentration 
in their CSF but this finding was not statistically significant. They were also younger than the patients 
with no virus-reactive OCBs. Patients with MS and HHV-6 infection have been noted to be younger 
in previous studies as well (Knox et al., 2000).  
No significant differences were found in Barkhof’s criteria among patients with or without virus-
reactive OCBs. The OCB status has earlier been associated with different MRI findings that are seen 
in different lesion patterns but not in differences in Barkhof’s criteria (Huttner et al., 2009). 
Differences in MRI findings have been reported in patients with virus-reactive OCBs in earlier studies 
as well (Virtanen et al., 2014).  
No significant differences were seen in the disease courses, durations, or clinical symptoms when 
comparing patients with HHV-6 -or VZV -reactive OCBs to patients without reactive OCBs. MS 
disease course heterogeneity and the small number of patients in this study provide a challenge to 
find significant clinical differences between the groups of patients.  
Only a portion of the patients with MS seemed to have some of the viruses, including HHV-6, 
involved in their disease and many patients had no signs of any viruses. It is therefore possible that 
the virus-reactive OCB status may simply be just be a part of a polyclonal activation and be a sign of 
an overly activated immune system. 
Interestingly, all the differences in the CSF parameters of the patients, in these separate studies, 
seemed to be parallel; patients with HHV-6 -or VZV-reactive OCBs had more OCBs, higher IgG index 
and lower protein concentration in their CSF, and they all were also younger than the patients who 
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had no virus-reactive OCBs at all. The parameters that gave significant results were, however, 
diverse in different studies (Table 7). The number of the patients in our study is too low for a decent 
comparison of statistical differences: Only clear differences may give a significant result and some 
of the true differences may lack statistical significance. 
The results seem to support the theory that patients who have signs of HHV-6 or VZV -infections 
seem to differ from the patients with no recent HHV-6 or VZV -infection. They seem to have signs 
of a possibly more aggressive intrathecal immunoglobulin synthesis with higher IgG index and more 
OCBs. They also seem to have active intrathecal HHV-6 or VZV antibody synthesis. This may support 
the theory that patients who have HHV-6 or VZV signs in their early MS may have these viruses 
somehow associated in their disease pathogenesis. Alternatively, there is no causative role for the 
viruses, but these patients who have immunologically more active disease may just be more prone 
to polyclonal activation of viral antibody production. 
It is reported that certain MS medications, that modulate the immune system, are able to induce 
difficult VZV reactivations in some patients, in addition to HHV-6 reactivations (Perez-Cesari et al., 
2005). It may be that activation of the virus, when the immune system is suppressed, somehow 
associates either by itself or by inducing polyclonal activation to the MS process. If so, these patients 
are at higher risk for the CNS complications that these viruses may induce. This would be noteworthy 
while treating these patients. 
5.2.1 Total number of OCB 
In many cases, patients with MS have a stable OCBs status and OCB banding pattern that has even 
been defined to be a unique “fingerprint” for each patient (Confavreux et al., 1986). The number of 
the bands may, however, change with time, also depending on the activity of the MS disease and 
on the effective treatments (von Glehn et al., 2012, Harrer et al., 2013, Axelsson et al., 2013, 
Mancuso et al., 2014, Thompson et al., 1983, Haertle et al., 2014). The same pattern is also evident 
with corticosteroid treatment in other autoimmune diseases with neurological involvement 
(McLean et al., 1995). 
Patients with MS disease also have differences in their disease characteristics depending on whether 
they have OCBs in the CSF, and if a patient has 10 or more OCBs it is even more predictive of MS 




a relevant role in MS pathogenesis (Bankoti et al., 2014). In addition, drugs that reduce B cells are 
effective in MS treatment. The number of OCBs, however, doesn’t seem to have direct correlation 
with the amount of active B cell clones (Petzold, 2013).  
It is still possible that the higher number of bands in the CSF and the intensity of the color and band 
thickness mean that the amount of antibodies in the CSF is higher and it may be caused by the more 
active production of antibodies in the CNS. It is a sign of immune system activation in the CSF. It 
doesn’t seem to correlate with the clinical course but it may be indicative of a difference in 
pathogenetic mechanisms. This is in parallel with the current study’s finding that patients with virus-
reactive OCBs have a higher number of OCBs. Patients with virus-reactive OCBs may have a different 
pathogenesis with a virus being involved. Alternatively, they may represent a subgroup of patients 
that are prone to mount more vivid immune reactions to external antigens. 
Only one CSF sample was available from each of the patients. In most cases it was taken near or 
during the time of their first clinically noted symptoms because a control lumbar puncture sampling 
is usually not clinically justified. Thus, the number of OCBs in the CSF of the patients cannot be 
compared to determine whether this differed during the disease course. In addition, the number of 
HHV-6 –or VZV –reactive OCBs could not be compared to determine whether they are stable or if 
they change during the disease course.  
One major weakness in our study is that we have a small number of patients from whom CSF and 
serum samples were analyzed. The small number of cases could possibly lead to inaccurate 
conclusions. The low number of patients also makes statistical analysis unreliable in finding all 
possible differences, especially in clinical course. Lumbar puncture is an invasive procedure which is 
not recommended unless necessary.  These CSF samples were, however, collected systematically 
from all patients that were treated in one hospital within a year. According to the clinic protocol, 
every patient with a relevant suspicion of MS underwent lumbar puncture sampling.  Therefore, 
even though the number of cases is low, the population of the study is rather representative of 
patients in the early phase of a demyelinating disease.    
54 
 
5.2.2 How can the small number of virus-reactive OCBs be explained, when compared to the total 
number of OCBs?  
The resolution of separate bands and the clearness of colors in the original IEF gel are clearly better 
when compared to the bands in the nitrocellulose membrane after affinity-driven immune blotting 
and immunoperoxidase staining. Some of the thickest bands in the membranes may contain several 
bands that would be seen as separate bands in the gel. In affinity-driven immune blotting, some of 
the antibodies in the bands can fail to transfer into the membrane and, therefore, don’t appear in 
the membrane. In the IEF gels, the OCBs are often located in a broad pH range (Figure 8). In the 
nitrocellulose membrane, the HHV-6-reactive bands were located only in a certain part of the 
banding pattern. VZV-reactive OCBs were also located only in certain part of the pattern. It seems 
that in addition to the HHV-6 or VZV-reactive OCBs, there are additional bands which are reactive 
with other antigens than HHV-6 or VZV. Three patients had both HHV-6 reactive OCBs and VZV-
reactive OCBs visible in the same CSF sample. IEF runs with different virus-antigens were performed 
separately in different runs. No markers were used that would enable locating individual OCBs and, 
therefore, comparison based on the location of individual bands in different runs is not easy. In 
these cases, the VZV-reactive and HHV-6- reactive bands were located in clearly different parts of 
the pattern, which makes the identification of these bands reliable. These patients truly seem to 
have both HHV-6- and VZV-reactive -OCBs at the same time. It may be a true immune reaction 
against the two pathogens or just a secondary unnecessary antibody production of B cells caused 
by activated immune system (polyclonal activation). There are several reports of co-infections 
especially involving herpes viruses (Gaeta et al., 2009, Al Fawaz et al., 2014, Mancuso et al., 2007). 
Co-expression of HHV-6 and VZV is also seen in the ability of these viruses to be latent in the same 
site at the same time (Hufner et al., 2007). Co-existence of HHV-6 and EBV DNA has also been 
associated with RRMS disease activity (Hollsberg et al., 2005). The patients seemed to have a clear 
timely relation with virus-reactive OCBs and their clinical symptoms (Figure 9) but the meaning of 
this finding requires more research.  
5.2.3 Virus-reactive OCBs; polyclonal activation or antibody production against relevant antigens?  
The presence of antibodies against measles and/or rubella and/or varicella (MRZ-reaction) in CSF is 
considered to be a highly typical characteristic in MS and it is considered to predict CIS progression 




2009, Stich et al., 2014). MRZ-reaction is thought to be a sign of polyclonal immune activation in an 
immune system dysfunction (Skorstad et al., 2009, Kulakowska et al., 2012). These reports suggest 
that virus-specific OCBs in the CSF are not produced against its own target and are not a sign of an 
infectious agent. Some reports suggest that HHV-6 antibodies are a part of a polyclonal immune 
response rather than a causative agent in MS (Derfuss et al., 2005).  
Besides relevant antibody production, virus infections may also trigger abnormal B cell cytokine 
responses (Bar-Or et al., 2010). This combination is probably seen in the high amount of IgG in the 
CSF and as a high number of OCBs. It has also been considered that MS is rather triggered by multiple 
infectious agents together than antibodies being just a product of a polyclonal activation (Krone et 
al., 2008). Antigen-driven immune response seems to dominate in MS pathogenesis  (Gilden, 2005) 
and B cells are natural target cells in the different therapies for MS (Krumbholz et al., 2012). 
 
5.3 MECHANISMS FOR HOW HHV-6 AND VZV COULD BE INVOLVED IN DEMYELINATION AND MS 
PATHOGENESIS 
The association of HHV-6 and VZV with the MS pathogenesis remains controversial. Both viruses are 
found in the early or active phase of the MS disease. Both viruses also seem to fit in to the viral 
theory of MS, especially HHV-6. It therefore seems plausible that HHV-6 and VZV could have some 
role in the disease progression. 
5.3.1 Cell-mediated and humoral autoimmunity theories of MS 
5.3.1.1 Molecular mimicry 
MBP-reactive T cells can be activated by HHV-6 through molecular mimicry because HHV-6 shares 
some identical sequence with MBP, which the T cells recognize (Tejada-Simon et al., 2003, Tait and 
Straus, 2008). After cross-reactivation, the T cells attack against the host myelin. This results in 
demyelination.  
5.3.1.2 Interaction with leukocytes 
 HHV-6 may activate CD4+ T-cells via its interaction with CD46 (Yao et al., 2010b). CD46 is a 
membrane co-factor protein that is one of the regulators in a complement cascade. CD46 is also a 
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cellular receptor for HHV-6A (Santoro et al., 1999). Increased levels of CD46 and HHV-6 infection 
have been reported in patients with MS (Fogdell-Hahn et al., 2005, Alvarez-Lafuente et al., 2009). 
Especially CD46 is associated with HHV-6A virions (Hammarstedt et al., 2007). HHV-6 may even 
induce leukocytes to travel into the CNS without producing an infection (Reynaud et al., 2014). 
HHV-6B uses the CD134 as a cellular receptor. CD134s are mainly located on activated T cells, but 
not on glial cells. (Tang et al., 2013) 
Invariant natural-killer T cells are one of the controls of VZV in human hosts and it is thought that 
abnormalities in these cells lead to VZV reactivation (Novakova et al., 2011). VZV can cause a non-
productive infection in neurons and prevent infected neurons to undergo apoptosis (Pugazhenthi 
et al., 2011, Yu et al., 2013). It may also have an impact on the immune system and lead to over-or 
under-regulation of the system. 
5.3.2 Direct virus infection of the CNS 
HHV-6A uses CD46 as a cellular receptor and enters into the target cell via the cellular-membrane 
lipid raft (Tang et al., 2008). CD46 is a highly expressed protein in the BBB, and it is thought that 
HHV-6 could use CD46 for passing the BBB into the CNS (Alvarez-Lafuente et al., 2009, Shusta et al., 
2002). This may be one mechanism that could explain how HHV-6A is capable of a direct CNS 
infection.  
HHV-6 is capable of directly infecting oligodendrocytes (Ahlqvist et al., 2005). It may induce 
apoptosis of oligodendrocytes and neurons (Gardell et al., 2006). It may also indirectly induce death 
of necrotic oligodendrocytes and therefore cause demyelination (Kong et al., 2003). HHV-6 may lyse 
infected target cells or it may activate inflammatory or immune reactions and induce an 
autoimmune reaction (Krueger and Ablashi, 2003). 
HHV-6 can directly infect the CNS and seroconversion may be seen until recovery (Agut, 2011). One 
entry mechanism is known to be the olfactory pathway (Harberts et al., 2011). One patient showed 
similar findings of a direct CNS infection associated with HHV-6 reactive OCBs in the CSF and no 
serum antibodies to either of the HHV-6 variants. Three patients with signs of a primary infection in 
the serum antibodies also had HHV-6-reactive OCBs present in their CSF at the same time. This 




VZV can infect axons and retrogradely transport itself into neuronal cell bodies (Markus et al., 2011). 
This may be one pathway for VZVs to enter the CNS.  
5.3.3 Gives access to other pathogens to infect the host CNS? 
HHV-6 can cause slight suppression for the human immune system and allow access to other factors 
(for example other viruses) to induce MS progression. This may be one possible explanation as to 
why some of our patients, who were diagnosed with MS, had an HHV-6 -co-infection with either the 
other HHV-6 –virus type or VZV. Co-infections of viruses have been reported previously in early MS 
(Ferro et al., 2012, Tomsone et al., 2001). HHV-6 has even been shown to increase the replication 
of JC viruses (JCV) (Yao et al., 2008). 
HHV-6 may cause immunosuppression through the ability to directly infect CD4+T cells (Lusso, 
2006). HHV-6 is also capable of inducing HHV-6- CD4+ and CD8+ -specific regulatory T cells that both 
suppress CD4+ T cells and reduce dendritic cell functions (Wang et al., 2014). HHV-6 seems to have 
an impact on the cytokine network. It is capable of modulating the synthesis of different cytokines, 
which leads to immunosuppressive effects for different cell types (i.e. macrophages, astrocytes, 





6 CONCLUSIONS AND FUTURE ASPECTS  
HHV-6 has been connected with MS progression in many studies, especially in the relapsing-
remitting type of the disease. Some studies dispute that HHV-6 is involved in the disease 
pathogenesis and the relation between HHV-6 and MS still remains at least partly controversial.  
In early MS and in other related demyelinating diseases of some patients, HHV-6 is seen as a 
serological primary infection and also in the CSF as HHV-6- reactive OCBs. It seems to play a role in 
the disease progression, at least in some patients. In immune competent adults, HHV-6 seems to 
have no typical clinical signs of a virus infection. 
In this study, differences between the patients who had VZV-reactive OCBs and the patients who 
had no VZV-reactive OCBs were similar to the case with HHV-6-reactive OCBs. The patients who had 
either VZV or HHV-6- reactive OCBs in their CSF had a statistically higher number of OCBs, higher 
IgG index, lower protein concentration, and they were younger than the patients who had no 
reactive OCBs. Significant differences were observed in the different parameters within VZV and 
HHV-6 OCB-reactive patients, but all the differences showed a similar trend. The small number of 
patients prevents detailed statistical analyses and definite conclusions. The results, however, 
support the theory of the association of HHV-6 and VZV with the disease pathogenesis and that they 
may even be triggering the MS progression in some patients. 
It seems that there are distinguishable subgroups formed by different viruses in the diseases with 
demyelination, and this can be seen as the presence of virus-reactive OCBs. It is likely that no single 
virus will be found to trigger MS, but more likely that many different viruses will be found to be 
involved in different “subgroups” of the disease course, as it seems to be with HHV-6. The diagnosis 
of HHV-6 and other herpes virus infections should be implemented in the differential diagnostic 
process to be able to treat herpesvirus induced neurological symptoms. 
There are antiviral drugs that are relatively safe and known to be effective in HHV-6 infections. 
Studies of antiviral therapy treatment against HHV-6 and its effect to the course of demyelination 
could give useful further information. The search for HHV-6 infection is relevant in the follow-up of 
MS patients who are on immunosuppressive therapies and hence at higher risk for the CNS 







Tämän väitöskirjatyön toteutumisessa on kulunut kaiken kaikkiaan lähes vuosikymmen. 
Tutkimustyötä olen tänä aikana tehnyt sekä Virologian laitoksella että Neurologian laitoksella, 
Lääketieteellisessä tiedekunnassa, Helsingin Yliopistossa. Haluan kiittää siitä mahdollisuudesta, että 
olen saanut tehdä tutkimustyötäni näissä laitoksissa, virologian laitoksen professori Kalle Sakselaa 
sekä neurologian professori Markus Färkkilää. 
Ohjaajalleni professori Markus Färkkilälle haluan antaa erityiset kiitokset koko väitöstyöni aikana 
saamastani sekä arvokkaasta asiantuntija-tuesta että myös vähintään yhtä arvokkaasta henkisestä 
tuesta. Lisäksi haluan kiittää häntä kaikesta siitä ajasta, jota hän on käyttänyt koko tämän väitöstyöni 
aikana. Ilman hänen tukeaan ja kannustustaan ei tämä väitöskirja olisi koskaan lopulta valmistunut.  
Neurologian ja virologian dosentti Marjaleena Koskiniemeä haluan erityisesti kiittää yhteisestä 
ajasta, jona hän toimi ohjaajanani. Hänen asiantuntemuksensa ja kiinnostuksensa lääketieteeseen 
sai minut alun perin lähtemään mukaan tähän väitöskirjatyöhön. Lisäksi haluan lämpimästi kiittää 
häntä myös mahdollisuudesta olla osana hänen tutkimusryhmäänsä.  
Ohjaajieni lisäksi koko väitöstyöni ajan on ollut vahvana asiantuntijatukena Kliinisen kemian dosentti 
Lasse Uotila, jota haluan lämpimästi kiittää yhteistyöstä, kaikesta antamastaan ajasta ja arvokkaista 
neuvoista sekä mielipiteistä että näkökumista kaikkien julkaisujen käsikirjoituksien sekä 
yhteenvedonkin sisältöjen osalta. Lisäksi haluan kiittää mahdollisuudesta kun sain toimia ja 
työskennellä kliinisen kemian tiloissa ja laboratoriossa. Haluan myös kiittää arvokkaasta 
tutkimuksessani käytettyjen näytteiden keräyksestä, joka toteutettiin hänen toimestaan. Olen myös 
erittäin kiitollinen hänen järjestämistään IEF-geeleistä, joita sain käyttää tutkimustyössäni. 
”Laboratorio-maailmaan” perehdyttämisestä haluan erityisesti kiittää FT Oskari Virtasta, joka 
kärsivällisesti ja käytännönläheisesti opetti (tällöin vielä) ”pientä kandia” toimimaan labrassa. Lisäksi 
haluan kiittää häntä kaikesta siitä ajasta ja asiantuntemuksestaan, jota hän on käyttänyt 
väitöskirjatyöni osajulkaisuihin. Erityiskiitos hänelle myöskin hänen asiantuntevista kommenteista 
ja korjausehdotuksista, joita sain yhteenvetooni häneltä myös jo sen kokoamisvaiheessa. 
FT Pekka Kolehmaista haluan myöskin erityisesti kiittää kaikesta siitä tuesta ja neuvoista, jotka 
mahdollistivat väitöskirjatyössäni tarvittavien labra-töiden toteutumisen. Häntä haluan myös kiittää 
kaikesta siitä ajasta ja asiantuntemuksesta, jota hän on käyttänyt erityisesti viimeisimmässä 
osajulkaisussani. Lisäksi haluan kiittää antoisasta yhteisestä ajasta, jonka vietimme yhteisessä 
toimistossa. 
Kliinisen mikrobiologian erikoislääkäri, hammaslääkäri ja LT Hannamari Välimaata haluan erityisesti 




Lisäksi haluan kiittää kaikkia julkaisuissani mukana olleita kanssakirjoittajia, jotka ovat antaneet 
oman asiantuntijaosaamisensa ja aikaansa tämän väitöstyöni osajulkaisuihin. 
Suuret kiitokset yhteenvetoni tarkastaneille esitarkastajille Turun Yliopiston Neurologian laitoksen 
dosentti Merja Soilu-Hänniselle sekä Turun yliopiston Virologian laitoksen dosentti Veijo Hukkaselle 
heidän asiantuntevista ja arvokkaista korjausehdotuksistaan sekä kommenteistaan, jotka auttoivat 
parantamaan yhteenvetoani.  
Lisäksi suuret kiitokset HUSLAB:in Kliinisen kemian proteiinikemian yksikön henkilökunnalle 
väitöskirjatyössäni käytettyjen näytteiden keräyksen toteutuksesta sekä heidän laboratoriossa 
työskentelyn ohjauksesta. Kiitokset Sari Parkkamäelle, joka oli sekä tekemässä että avustamassa 
minua osassa näytteiden analyyseistä. Kiitokset Neurologian pkl:n henkilökunnalle sekä Markus 
Färkkilän silloiselle sihteerille avusta potilaspapereiden keräyksessä.  
Suuret kiitokset myös rakkaille kollegoilleni ja ystävilleni Lotalle sekä Tiinalle, joilta sain vapaaseen 
käyttööni tässäkin kirjassa käytetyt kuvat virusinfektioista. Kyseisiä kuvia olen saanut käyttää myös 
pitämässäni esitelmässä World Congress of Neurology:ssa vuonna 2013. 
Erityiskiitokset haluan antaa lisäksi rakkaille ystävilleni Anskulle ja Juulille, jotka ovat olleet suurena 
henkisenä tukena ja antaneet myöskin käytännön tukea ja vinkkejä koko väitöstyöni ajan. 
Haluan osoittaa lisäksi erityiskiitokset isälleni Jarkolle, sisarelleni Jutalle ja appivanhemmilleni 
Nikulle ja Mellulle, jotka ovat olleet (ja toivon mukaan ovat jatkossakin) tukemassa ajoittain hyvinkin 
ruuhkaisilta tuntuvia ruuhka-vuosia.  
Viimeisimpänä, mutta ei missään nimessä vähäisimpänä, haluan kiittää rakasta perhettäni Turoa ja 
Monaa, jotka ovat olleet vahvana taustajoukkona aina kun sitä olen enemmän tai vähemmän 
tarvinnut. Lisäksi he ovat olleet muistuttamassa minua sen tärkeydestä, että elämää on myös työn 
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